Literature DB >> 27040974

American tegumentary leishmaniasis: T-cell differentiation profile of cutaneous and mucosal forms-co-infection with Trypanosoma cruzi.

Cecilia Parodi1,2, María F García Bustos3, Alejandra Barrio4, Federico Ramos3, Ana G González Prieto4, María C Mora3, Patricia Baré5, Miguel A Basombrío3, María M de Elizalde de Bracco5.   

Abstract

American tegumentary leishmaniasis displays two main clinical forms: cutaneous (CL) and mucosal (ML). ML is more resistant to treatment and displays a more severe and longer evolution. Since both forms are caused by the same Leishmania species, the immunological response of the host may be an important factor determining the evolution of the disease. Herein, we analyzed the differentiation and memory profile of peripheral CD4(+) and CD8(+) T lymphocytes of patients with CL and ML and their Leishmania-T. cruzi co-infected counterparts. We measured the expression of CD27, CD28, CD45RO, CD127, PD-1 and CD57, together with interferon-γ and perforin. A highly differentiated phenotype was reflected on both T subsets in ML and preferentially on CD8(+) T cells in CL. A positive trend toward a higher T differentiation profile was found in T. cruzi-infected CL and ML patients as compared with Leishmania single infections. Association between CD8(+) T-cell differentiation and illness duration was found within the first year of infection, with progressive increase of highly differentiated markers over time. Follow-up of patients with good response to therapy showed predominance of early differentiated CD8(+) T cells and decrease of highly differentiated cells, while patients with frequent relapses presented the opposite pattern. CD8(+) T cells showed the most striking changes in their phenotype during leishmaniasis. Patients with long-term infections showed the highest differentiated degree implying a relation between T differentiation and parasite persistence. Distinct patterns of CD8(+) T differentiation during follow-up of different clinical outcomes suggest the usefulness of this analysis in the characterization of Leishmania-infected patients.

Entities:  

Keywords:  Cutaneous leishmaniasis; Differentiation and memory phenotype; Leishmania–T. cruzi co-infection; Mucosal leishmaniasis; Peripheral T lymphocytes

Mesh:

Substances:

Year:  2016        PMID: 27040974     DOI: 10.1007/s00430-016-0455-0

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  51 in total

Review 1.  Advances in leishmaniasis.

Authors:  Henry W Murray; Jonathan D Berman; Clive R Davies; Nancy G Saravia
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

2.  Leishmanial antigens in the diagnosis of active lesions and ancient scars of American tegumentary leishmaniasis patients.

Authors:  A Schubach; T Cuzzi-Maya; A V Oliveira; A Sartori; M P de Oliveira-Neto; M S Mattos; M L Araújo; W J Souza; F Haddad; M de A Perez; R S Pacheco; H Momen; S G Coutinho; M C de Almeida Marzochi; K B Marzochi; S C da Costa
Journal:  Mem Inst Oswaldo Cruz       Date:  2001-10       Impact factor: 2.743

3.  Immunological correlates of cure in the first American cutaneous leishmaniasis patient treated by immunotherapy in Argentina. A case report.

Authors:  María Fernanda García Bustos; Alejandra Beatriz Barrio; Cecilia Maria Parodi Ramoneda; Federico Ramos; María Celia Mora; Jacinto Convit; Miguel Angel Basombrío
Journal:  Invest Clin       Date:  2011-12       Impact factor: 0.683

4.  Cell mediated immunity in American cutaneous and mucosal leishmaniasis.

Authors:  E M Carvalho; W D Johnson; E Barreto; P D Marsden; J L Costa; S Reed; H Rocha
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

5.  Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection.

Authors:  Joseph N Blattman; E John Wherry; Sang-Jun Ha; Robbert G van der Most; Rafi Ahmed
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

6.  Progressive CD127 down-regulation correlates with increased apoptosis of CD8 T cells during chronic HIV-1 infection.

Authors:  Shu-Ye Zhang; Zheng Zhang; Jun-Liang Fu; Fu-Biao Kang; Xiang-Sheng Xu; Wei-Min Nie; Chun-Bao Zhou; Min Zhao; Fu-Sheng Wang
Journal:  Eur J Immunol       Date:  2009-05       Impact factor: 5.532

7.  Cytokine profile and pathology in human leishmaniasis.

Authors:  A Ribeiro-de-Jesus; R P Almeida; H Lessa; O Bacellar; E M Carvalho
Journal:  Braz J Med Biol Res       Date:  1998-01       Impact factor: 2.590

8.  Regulatory T cells in the pathogenesis and healing of chronic human dermal leishmaniasis caused by Leishmania (Viannia) species.

Authors:  Daniel Rodriguez-Pinto; Adriana Navas; Víctor Manuel Blanco; Lady Ramírez; Daniel Garcerant; Adriana Cruz; Noah Craft; Nancy Gore Saravia
Journal:  PLoS Negl Trop Dis       Date:  2012-04-24

9.  DNA sequencing confirms the involvement of Leishmania (L.) amazonensis in American tegumentary leishmaniasis in the state of São Paulo, Brazil.

Authors:  Angela Rapela Medeiros; Wilson A Silva; Ana Maria Roselino
Journal:  Clinics (Sao Paulo)       Date:  2008-08       Impact factor: 2.365

10.  B7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infections.

Authors:  Trupti Joshi; Susana Rodriguez; Vladimir Perovic; Ian A Cockburn; Simona Stäger
Journal:  PLoS Pathog       Date:  2009-05-15       Impact factor: 6.823

View more
  4 in total

1.  Germacranolide-type sesquiterpene lactones from Smallanthus sonchifolius with promising activity against Leishmania mexicana and Trypanosoma cruzi.

Authors:  Jerónimo L Ulloa; Renata Spina; Agustina Casasco; Patricia B Petray; Virginia Martino; Miguel A Sosa; Fernanda M Frank; Liliana V Muschietti
Journal:  Parasit Vectors       Date:  2017-11-13       Impact factor: 3.876

Review 2.  Tegumentary leishmaniasis and coinfections other than HIV.

Authors:  Dalila Y Martínez; Kristien Verdonck; Paul M Kaye; Vanessa Adaui; Katja Polman; Alejandro Llanos-Cuentas; Jean-Claude Dujardin; Marleen Boelaert
Journal:  PLoS Negl Trop Dis       Date:  2018-03-01

3.  Risk factors for antimony treatment failure in American Cutaneous Leishmaniasis in Northwestern-Argentina.

Authors:  María F García-Bustos; Gabriela González-Prieto; Alberto E Paniz-Mondolfi; Cecilia Parodi; Josefina Beckar; Sibila Monroig; Federico Ramos; María C Mora; Lourdes A Delgado-Noguera; Yoshihisa Hashiguchi; Daniela Jaime; Sonia Moreno; Luisa Ruiz-Morales; César G Lemir; Alejandra Barrio
Journal:  PLoS Negl Trop Dis       Date:  2021-01-26

4.  Circulating Senescent T Cells Are Linked to Systemic Inflammation and Lesion Size During Human Cutaneous Leishmaniasis.

Authors:  Luciana P Covre; Régia F Martins; Oliver P Devine; Emma S Chambers; Milica Vukmanovic-Stejic; Juliana A Silva; Reynaldo Dietze; Rodrigo R Rodrigues; Herbert L de Matos Guedes; Aloísio Falqueto; Arne N Akbar; Daniel C O Gomes
Journal:  Front Immunol       Date:  2019-01-04       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.